Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment A Phase 1 clinical trial concluded that setidegrasib targets KRAS G12D mutations effectively, showing promise for lung and pancreatic cancer patients.

Groundbreaking Phase 1 Study Shows Promising Results for KRAS-Targeted Lung and Pancreatic Cancer Treatment #United_States #Florida_Cancer_Specialists #Fort_Myers #KRAS_G12D #setidegrasib

D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications D3 Bio has received FDA clearance for two IND applications, paving the way for crucial cancer trials involving new therapeutics targeting KRAS mutations.

D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications #Shanghai #USA #KRAS_G12D #D3_Bio #elisrasib

Bayer and Kumquat Biosciences Collaborate on Precision Oncology to Combat KRAS G12D Mutations Bayer and Kumquat Biosciences announce an exclusive collaboration to develop a KRAS G12D inhibitor, targeting high unmet needs in cancer treatment.

Bayer and Kumquat Biosciences Collaborate on Precision Oncology to Combat KRAS G12D Mutations #USA #San_Diego #Bayer #KRAS_G12D #Kumquat